[Retracted] Evaluation of lncRNA FOXD3-AS1 as a Biomarker for Early-Stage Lung Cancer Diagnosis and Subtype Identification

Figure 5

The efficiency of plasma FOXD3-AS1 in LC diagnosis and SCLC identification at early stage. (a)–(g) ROC curves used to validate the discrimination efficiency of plasma FOXD3-AS1 for early-stage SCLC vs. HS (a), early-stage LUAD vs. HS (b), early-stage LUSC vs. HS (c), early-stage LC vs. HS (d), early-stage SCLC vs. early-stage LUAD (e), early-stage SCLC vs. early-stage LUSC (f), and early-stage LUAD vs. early-stage LUSC (g).

(a)

(b)

(c)

(d)

(e)

(f)

(g)